We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com. Temozolomide with radiation therapy improved 5- and ...
Adjuvant temozolomide post-radiotherapy significantly improves survival in 1p/19q non-co-deleted anaplastic astrocytomas, especially in IDH-mutated cases, reducing mortality risk by 35%. Concurrent ...
Voranigo and Temodar combination showed no serious side effects or dose-limiting toxicities in IDH1/2-mutant glioma patients. Treatment-emergent side effects led to dose reductions in 42.9% of ...
Treatment of Localized Nonorbital, Nonparameningeal Head and Neck Rhabdomyosarcoma: Lessons Learned From Intergroup Rhabdomyosarcoma Studies III and IV Purpose: Temozolomide (Temodar; Schering-Plough ...
“The paper revealed a critical role of GBP3 involving multiple [temozolomide] resistance mechanisms.” “The acquired resistance to the standard adjutant radiochemotherapy including temozolomide has ...
“We found that the 10-year survival rate was 70% with the combined treatment with temozolomide chemotherapy and radiation, compared to 47% with radiation alone as the initial approach. This discovery ...
A total of 144 patients were enrolled between April 2013 and March 2016 to temozolomide (n = 72) or capecitabine and temozolomide (n = 72); the primary analysis population included 133 eligible ...
Allarity Therapeutics has announced a Phase 2 clinical trial to evaluate the combination of stenoparib, a dual PARP/Wnt pathway inhibitor, with temozolomide for patients with recurrent Small Cell Lung ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results